Immix Biopharma (IMMX) Institutional Ownership $2.49 +0.06 (+2.47%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Immix Biopharma (NASDAQ:IMMX)CurrentInstitutional OwnershipPercentage11.26%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$205.61KNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$642.55K Get IMMX Insider Trade Alerts Want to know when executives and insiders are buying or selling Immix Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IMMX Institutional Buying and Selling by Quarter Immix Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/13/2025 Tocqueville Asset Management L.P.29,300$49K0.0%-23.5%0.105% 2/14/2025 Jane Street Group LLC17,523$39K0.0%N/A0.064% 2/6/2025 SBI Securities Co. Ltd.17,500$38K0.0%N/A0.064% 1/13/2025 FNY Investment Advisers LLC28,750$63K0.0%N/A0.105% 11/16/2024 Geode Capital Management LLC150,082$224K0.0%+5.6%0.546% 10/22/2024 Private Advisor Group LLC34,325$51K0.0%-47.3%0.130% 8/16/2024 Invst LLC27,000$57K0.0%N/A0.102% 8/12/2024 XTX Topco Ltd17,663$35K0.0%-66.2%0.067% 8/9/2024 Renaissance Technologies LLC154,685$306K0.0%-41.7%0.586% 8/7/2024 AIGH Capital Management LLC1,406,680$2.79M0.9%-9.5%5.326% Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 5/10/2024 Tocqueville Asset Management L.P.37,800$116K0.0%+89.0%0.143% 4/26/2024 Tritonpoint Wealth LLC24,526$75K0.0%N/A0.093% 2/7/2024 Jump Financial LLC18,500$128K0.0%N/A0.093% 2/6/2024 Private Advisor Group LLC99,775$690K0.0%N/A0.502% 2/1/2024 OLD National Bancorp IN10,000$69K0.0%N/A0.050% 1/30/2024Imprint Wealth LLC34,483$239K0.2%+49.4%0.174% 11/9/2023 Tocqueville Asset Management L.P.12,000$41K0.0%N/A0.061% 10/23/2023 Commonwealth Equity Services LLC28,855$99K0.0%+26.4%0.147% 7/28/2023 Koshinski Asset Management Inc.51,001$137K0.0%N/A0.339% 7/25/2023 UMB Bank n.a.72,639$195K0.0%-26.8%0.483% 4/11/2023 UMB Bank n.a.99,300$181K0.0%N/A0.714% 2/10/2023 Murchinson Ltd.67,200$154K0.0%N/A0.482% 2/7/2023Lynwood Capital Management Inc.25,000$58K0.1%N/A0.179% 2/1/2023 Bank of Montreal Can15,000$36K0.0%N/A0.108% 5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115% 2/14/2022 Altium Capital Management LP122,388$436K0.1%N/A1.616% 2/14/2022 Murchinson Ltd.695,600$2.48M0.2%N/A9.183% 2/9/2022 Context Capital Management LLC11,532$41K0.0%N/A0.152% 2/2/2022 PVG Asset Management Corp20,000$71K0.3%N/A0.264% 2/1/2022Eidelman Virant Capital29,856$103K0.0%N/A0.394% (Data available from 1/1/2016 forward) IMMX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IMMX shares? During the previous two years, 17 institutional investors and hedge funds held shares of Immix Biopharma. The most heavily invested institutionals were AIGH Capital Management LLC ($2.79M), Renaissance Technologies LLC ($306K), Imprint Wealth LLC ($239K), Geode Capital Management LLC ($224K), UMB Bank n.a. ($195K), Koshinski Asset Management Inc. ($137K), and Jump Financial LLC ($128K).Learn more on IMMX's institutional investors. What percentage of Immix Biopharma stock is owned by institutional investors? 11.26% of Immix Biopharma stock is owned by institutional investors. Learn more on IMMX's institutional investor holdings. Which institutional investors have been buying Immix Biopharma stock? Of the 13 institutional investors that purchased Immix Biopharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Private Advisor Group LLC ($99.78K), Koshinski Asset Management Inc. ($51.00K), Tocqueville Asset Management L.P. ($29.80K), FNY Investment Advisers LLC ($28.75K), Invst LLC ($27K), Tritonpoint Wealth LLC ($24.53K), and Jump Financial LLC ($18.50K). How much institutional buying is happening at Immix Biopharma? Institutional investors have bought a total of 349,759 shares in the last 24 months. This purchase volume represents approximately $1.50M in transactions. Which Immix Biopharma major shareholders have been selling company stock? The following institutional investors have sold Immix Biopharma stock in the last 24 months: AIGH Capital Management LLC ($148.32K), Renaissance Technologies LLC ($110.82K), XTX Topco Ltd ($34.53K), Private Advisor Group LLC ($30.85K), UMB Bank n.a. ($26.66K), and Tocqueville Asset Management L.P. ($9K). How much institutional selling is happening at Immix Biopharma? Institutional investors have sold a total of 360,180 shares in the last 24 months. This volume of shares sold represents approximately $714.27K in transactions. Related Companies Terns Pharmaceuticals Institutional Ownership Cidara Therapeutics Institutional Ownership Candel Therapeutics Institutional Ownership Aquestive Therapeutics Institutional Ownership Tonix Pharmaceuticals Institutional Ownership Palvella Therapeutics Institutional Ownership Allogene Therapeutics Institutional Ownership Monte Rosa Therapeutics Institutional Ownership Tango Therapeutics Institutional Ownership Corvus Pharmaceuticals Institutional Ownership This page (NASDAQ:IMMX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.